Could Canopy Growth’s (TSX:WEED) Deal With Acreage Fall Through?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) investors were excited about the prospect of a potential deal with a U.S. cannabis company, but it may all be for naught.

| More on:
Businessman pulling out wooden brick from toppling stack

Image source: Getty Images.

Canopy Growth (TSX:WEED)(NYSE:CGC) saw its stock get a big boost when the company announced that it had a deal in place to acquire Acreage Holdings (CNSX:ACRG.U) last month. Although the purchase is conditional and might take years before it is realized, that didn’t stop investors from jumping on the bandwagon. The stock ended up climbing to around $70 a share; it hasn’t hit that mark since October.

However, we recently learned that not everyone is thrilled with the acquisition, and there might be a real chance the deal doesn’t get approved by Acreage shareholders. Earlier this week, Marcato Capital Management, which owns 2.7% of Acreage, said that it would be voting against the proposed deal and, in an open letter, stated its concerns.

Marcato believes Acreage is undervalued in the proposed deal

In its letter, Marcato describes the deal as being a “value-destructive transaction and not in the best interests of shareholders.” Those are some harsh words for what would be the largest deal yet in the industry, valued at about US$3.4 billion. One of the items that the letter looks at is the relative price movement of the shares since the announcement, pointing out that while Acreage shares have fallen, Canopy Growth’s have risen, suggesting that shareholders know it’s a much better deal for Canopy Growth than it is for Acreage.

Marcato also believes that Acreage’s valuation, along with other cannabis companies, will “skyrocket” once U.S. legalization takes place. The letter also points out that Acreage didn’t seek out other potential deals and suggests that there could be a “large universe of potential bidders” that would express interest, including from the beer and tobacco industries.

The only problem with that is we haven’t seen many big companies do anything besides kick tires on what’s still a very sensitive industry for them to get involved in. And so it’s a big assumption, to say the least, that there’d be such significant interest given that we’ve seen few large deals thus far, especially involving other industries.

Why the arguments aren’t strong

The letter relies on valuation multiples, price targets, projected 2020 EBITDA numbers, and recent price movement to justify its stance. We’ve already seen in the industry how little valuations matter and how quickly projections can get adjusted, and so to rely on that to make a case is weak at best.

There are too many assumptions built into the reasoning, and Marcato doesn’t recognize Acreage’s own risks in the deal either, that with rising competition and potentially bigger players getting involved, their position in the industry is far from guaranteed.

Bottom line

Ultimately, it’s going to come down to whether Acreage investors can be swayed by Marcato’s points and if they’ll be enough to get the votes needed to nix the deal with Canopy Growth. Activist investors can have a big impact on a stock, even though they lack controlling or significant interest in the company. And with a key investor so strongly opposed to the deal, there’s a real possibility that it might not go through, and that could result in Canopy Growth’s stock seeing a correction.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »